VHCP Management II as of Dec. 31, 2017
Portfolio Holdings for VHCP Management II
VHCP Management II holds 18 positions in its portfolio as reported in the December 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Avexis | 27.5 | $115M | 1.0M | 110.67 | |
| Biohaven Pharmaceutical Holding | 11.1 | $46M | 1.7M | 26.98 | |
| Ascendis Pharma A S (ASND) | 10.7 | $45M | 1.1M | 40.06 | |
| Argenx Se (ARGX) | 9.8 | $41M | 650k | 63.10 | |
| Zogenix | 8.2 | $34M | 854k | 40.05 | |
| Anaptysbio Inc Common (ANAB) | 6.8 | $29M | 283k | 100.72 | |
| Dbv Technologies | 5.0 | $21M | 674k | 30.70 | |
| Obseva Sa | 4.7 | $19M | 2.0M | 9.76 | |
| Savara (SVRA) | 4.5 | $19M | 1.3M | 14.84 | |
| BioCryst Pharmaceuticals (BCRX) | 2.9 | $12M | 2.5M | 4.91 | |
| Bellerophon Therapeutics | 2.3 | $9.7M | 4.1M | 2.33 | |
| Edge Therapeutics | 2.2 | $9.1M | 975k | 9.37 | |
| Spero Therapeutics (SPRO) | 1.4 | $5.7M | 486k | 11.75 | |
| Ra Pharmaceuticals | 1.1 | $4.6M | 545k | 8.50 | |
| Catalyst Biosciences | 0.8 | $3.2M | 236k | 13.64 | |
| Akari Therapeutics | 0.4 | $1.8M | 426k | 4.33 | |
| ARCA biopharma | 0.3 | $1.5M | 1.1M | 1.35 | |
| Lipocine | 0.3 | $1.3M | 387k | 3.44 |
